article Open AccessTop 1% cited

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Breast Cancer Research and Treatment · 2019 · Vol. 174(3) · pp. 719–729

Hope S. Rugo✉(UCSF Helen Diller Family Comprehensive Cancer Center)Richard S. Finn(University of California, Los Angeles)Véronique Dièras(Centre Eugène Marquis)Johannes Ettl(Technical University of Munich)Oleg Lipatov(Republican Oncological Clinical Dispensary)Anil A. Joy(University of Alberta)Nadia Harbeck(Ludwig-Maximilians-Universität München)Aurelio CastrellonShrividya Iyer(Pfizer (United States))Dongrui R. Lu(Pfizer (United States))A. Mori(Pfizer (Italy))Eric Gauthier(Pfizer (United States))Cynthia Huang Bartlett(Pfizer (United States))Karen A. Gelmon(BC Cancer Agency)Dennis J. Slamon(University of California, Los Angeles)

View via DOI Full-text PDF

Abstract

With approximately 15 months of additional follow-up, palbociclib plus letrozole continued to demonstrate improved PFS compared with placebo plus letrozole in the overall population and across all patient subgroups, while the safety profile remained favorable and quality of life was maintained. These data confirm that palbociclib-letrozole should be considered the standard of care for first-line therapy in patients with ER+/HER2- ABC, including those with low disease burden or long disease-free interval. Sponsored by Pfizer; ClinicalTrials.gov: NCT01740427.

Advanced Breast Cancer Therapies Cancer-related Molecular Pathways HER2/EGFR in Cancer ResearchPalbociclibLetrozoleMedicineBreast cancerOncologyInternal medicinePlaceboMetastatic breast cancerHazard ratioEstrogen receptor

MeSH terms

LetrozoleAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsDouble-Blind MethodFemaleHumansPiperazinesPyridinesQuality of LifeReceptors, EstrogenTreatment OutcomePostmenopauseReceptor, ErbB-2Erb-b2 Receptor Tyrosine Kinases